HARBIN, China, April 27 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced the appointment of Mr. Dianjun Pi to its board of directors effective April 26, 2010, and that the Company has established nominating and compensation committees.
Mr. Pi joined Renhuang in 2004 as an Executive Manager. Prior to his tenure with the Company, he served as Assistant General Manager of Kuihua Pharmaceutical Group Co., Ltd. a drug producer located in Heilongjiang Province. Between 1992 and 2003, he served as the Vice President of China Resources Snow Co. Ltd., a national beverage firm.
Renhuang also appointed Dr. Changxiong Sun, independent director, to serve as the chairman of the nominating committee and Mr. Bingchun Wu, independent director, to serve as the chairman of the compensation committee.
"We are pleased to announce the establishment of our nominating and compensation committees which reflects our firm commitment to meet the highest standards of corporate governance," said Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "I would like to extend my work appreciation to Dianjun Pi and welcome him to our board. Mr. Pi has made valuable contributions to Renhuang's success and we are confident that his expertise will positively contribute to the board's discussions and meetings, furthering our goal of building a high-growth pharmaceuticals company."
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to achieve its financial guidance, ability to list its shares on a senior stock exchange, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
Company Contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Tel: +86-451-5392-5461 Email: email@example.com CCG Investor Relations: Ms. Lei Huang, Account Manager Tel: +1-646-833-3417 (New York) Email: firstname.lastname@example.org Web: www.ccgirasia.com Mr. Crocker Coulson, President Tel: +1-646-213-1915 (New York) Email: email@example.com
|SOURCE Renhuang Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved